Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium is the major intracellular cation; it is essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac and skeletal muscle, and normal renal function. Dextrose is a source of calories and fluid. Sodium chloride is an electrolyte replenisher.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous, 10-20 mEq/hour, not to exceed 40 mEq per dose or 200 mEq per day; rate not to exceed 1 mEq/kg/hour. Typical maintenance: 40-80 mEq/day.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Not applicable as potassium is not eliminated by first-order kinetics; clearance depends on renal function (GFR) and tubular handling. In patients with normal renal function, plasma potassium declines rapidly after IV infusion, with a distribution half-life of approximately 1 hour and an elimination half-life of 12-24 hours for excess potassium, but this is clinically not used. The terminal half-life is not defined due to physiological regulation.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Primarily renal (90% or more) as potassium ion via glomerular filtration and tubular secretion; minimal biliary/fecal (<5%).
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."